mercredi 26 juillet 2017

Onco Actu du 26 juillet 2017

1. Biologie

Brain tumour’s faulty genetics uncovered [Cancer Research UK]

4.5 Dép., diag. & prono. - Colorectal

Exact Sciences Again Boosts Sales Projections for Flagship Product [Xconomy]

5. Traitements

Breaking the genetic resistance of lung cancer and melanoma – major step in treating some of the hardest to kill cancers [Monash University]

Probe Miner: a new resource for objective, large-scale assessment of chemical tools [Institute of Cancer Research]

5.12.4 Immunothérapies - Essais

MSD’s Keytruda hits rare snag, floundering in confirmatory trial [Pharmafile]

5.12.5 Immunothérapies - Pharma

Merck faces cancer drugs setback ahead of rival AstraZeneca's landmark trial results [The Telegraph]

5.2 Pharma

Onconova eyes 'RASopathy' diseases as new targets for its lead drug [Fierce Biotech]

5.2.3 Pharma - économie

Lilly puts two-thirds of midphase cancer pipeline up for sale in major shake-up of R&D priorities [Fierce Biotech]

Celgene Settles Lawsuit Over Improper Promotion of Cancer Drugs [Wall Street Journal]

Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs [NY Times]

5.3 Traitements - FDA, EMA, NICE...

Adding ‘right to try’ to FDA user fee bill would undermine the agency’s work [STAT]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia [NCI]

6.1 Observation

Cancer Rates Higher Among Patients with Primary Immunodeficiency Diseases [Roswell Park Cancer Institute]

6.11 Patients

Cancer patients in chemo ward may influence each other's survival [Reuters]

6.12 Ethique

Genes, cells, and biobanks: Yes, there’s still a consent problem [PLoS Biology]

6.7.1 Bioinformatique

Growth in next-generation sequencing informatics market fueled by big data [European Pharmaceutical Review]

6.9 Controverses

It will be much harder to call new findings ‘significant’ if this team gets its way [Science]